79% effective in the US test

LONDON – The results of a large US trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective in preventing serious illness and hospitalization .

The vaccine’s safety and efficacy analysis, released on Monday, was based on 32,449 participants in a phase 3 trial.

It comes shortly after a wave of countries temporarily suspended use of the vaccine following reports of blood clots in some vaccinated people. Health experts have sharply criticized the move, citing a lack of data, while analysts have expressed concern about the impact on vaccine uptake as the virus continues to spread.

Germany, France, Italy and Spain are among those who resumed use of the Oxford-AstraZeneca vaccine after the European medicines regulator said its initial investigation into possible side effects concluded that the vaccine was both safe and effective.

AstraZeneca said an independent council did not identify any safety issues related to the shooting. They also performed a specific examination for blood clots as well as cerebral venous sinus thrombosis, an extremely rare blood clot in the brain, with the help of an independent neurologist.

The Data Safety Oversight Board “found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. Specific search for CVST did not find any. event in this essay. “

Ann Falsey, professor of medicine at the University of Rochester, USA, and co-principal investigator of the trial, said: “This analysis validates the AstraZeneca COVID-19 vaccine as a vaccination option extra essential, providing the confidence that adults of all ages can benefit from protection against the virus. “